Xarelto国内价格

Rivaroxaban (Xarelto) was approved for marketing in Canada and the European Union on September 15 and October 1, 2008 respectively. Rivaroxaban (Xarelto) was approved for marketing by the State Food and Drug Administration in March 2009. Approved by the FDA on July 1, 2011, the drug is used to prevent deep vein thrombosis in patients undergoing knee or hip replacement surgery. Rivaroxaban (Xarelto) is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Rivaroxaban (Xarelto) does not inhibit thrombin and has not been shown to have an effect on platelets. A dose-dependent inhibitory effect of rivaroxaban (Xarelto) on factor xa activity has been observed in humans. Rivaroxaban (Xarelto, Xarelto) dose-dependently inhibits the activity of Factor In clinical practice, rivaroxaban (Xarelto, Xarelto) is mainly used to prevent thrombosis or after surgery.

Price: 1. Rivaroxaban (Xarelto, Xarelto) US price: Specification: 10mg-10 tablets/box, pharmacy price: US$156.24; Specification: 15mg-30 tablets/box, pharmacy price: US$438.67; Specification: 20mg-30 tablets/box, pharmacy price: US$553.65. 2. Price of rivaroxaban (Xarelto, Xarelto) in China: Domestic rivaroxaban (Xarelto, Xarelto) is an original drug produced by Bayer Pharma AG/Germany Bayer Pharmaceuticals. Specification: 10mg-5 tablets/box, priced at about 138$; Specification: 15mg-7 tablets/box, priced at about 199$; Specification: 20mg-7 tablets/box, priced at about 263$. 3. The specifications of rivaroxaban (Xarelto, Xarelto) listed abroad are 15mg*28 tablets; the price of 20mg*28 tablets is around $600.